THE 4 PRs THAT WILL SURGE THE BIEL PPS TO $1
Below are the four press releases that will ignite the BIEL breakout and drive the PPS toward the long‑awaited $1 milestone. Each PR builds on the previous one, creating a compounding momentum cycle that the market cannot ignore.
PR #1 — BIEL’s AI Pivot + ActiPatch’s Zero‑Cost Deployment + Stock as an AI Vehicle
This is the visibility catalyst.
BIEL’s ActiPatch is already market‑ready, already FDA‑cleared, and requires no development or startup cost for partners. That alone puts BIEL in a different category from early‑stage med‑tech companies that burn millions before revenue.
But the real spark is the AI pivot.
ActiPatch becomes the hardware layer for AI‑driven bioelectronic pain therapy — the physical delivery system for Electrome’s AI platform. This is the same “AI + hardware” convergence that sent other companies soaring.
And unlike private AI‑health startups, BIEL is publicly traded, giving anyone a direct, accessible vehicle to participate in the AI frenzy.
This PR introduces:
BIEL’s role in the AI healthcare ecosystem
ActiPatch as the ready‑to‑deploy hardware platform
Zero R&D cost, zero regulatory lag, zero product‑development delay
BIEL stock as the public gateway to the AI‑bioelectronic revolution
This is the PR that wakes up the market.
PR #2 — BIEL Confirms Profitability Path as Revenues Accelerate
This is the credibility catalyst.
BIEL announces that rising ActiPatch demand, expanding distribution, and new partnerships are pushing the company toward near‑term profitability.
Key points:
Revenue growth quarter over quarter
Expanding U.S. and international distribution
Increasing reorder volume
Lower manufacturing cost per unit
Clear timeline to profitability
This PR signals to the market that BIEL is no longer a speculative story — it’s a scaling business with real revenue traction.
PR #3 — BIEL Financials Becoming Current + Quarterly Reporting Begins
This is the institutional catalyst.
BIEL announces that it is completing the process of bringing its financials current and audited, and will begin quarterly reporting going forward.
This unlocks:
Global liquidity
Access to new investors
Eligibility for uplisting pathways
Institutional visibility
Analyst coverage potential
This PR removes the final barrier preventing large money from entering the stock.
PR #4 — BIEL Announces Stock Buyback Program After Loans Are Paid Off
This is the valuation catalyst.
Once loans are paid off, BIEL announces a share buyback program — a powerful signal of confidence and a direct mechanism to increase shareholder value.
A buyback:
Reduces the float
Increases EPS
Strengthens price stability
Attracts long‑term investors
Demonstrates financial discipline
This is the PR that transforms BIEL from a turnaround story into a high‑growth, shareholder‑focused company.
THE COMPOUNDING EFFECT
Each PR builds on the previous one:
Visibility (AI pivot + zero‑cost ActiPatch + stock as AI vehicle)
Credibility (profitability approaching)
Legitimacy (audited financials + quarterly reporting)
Valuation Power (stock buyback)
This sequence is how a sub‑penny stock becomes a story stock, then a momentum stock, then a fundamental growth stock, and finally a $1+ stock.
Below are the four press releases that will ignite the BIEL breakout and drive the PPS toward the long‑awaited $1 milestone. Each PR builds on the previous one, creating a compounding momentum cycle that the market cannot ignore.
PR #1 — BIEL’s AI Pivot + ActiPatch’s Zero‑Cost Deployment + Stock as an AI Vehicle
This is the visibility catalyst.
BIEL’s ActiPatch is already market‑ready, already FDA‑cleared, and requires no development or startup cost for partners. That alone puts BIEL in a different category from early‑stage med‑tech companies that burn millions before revenue.
But the real spark is the AI pivot.
ActiPatch becomes the hardware layer for AI‑driven bioelectronic pain therapy — the physical delivery system for Electrome’s AI platform. This is the same “AI + hardware” convergence that sent other companies soaring.
And unlike private AI‑health startups, BIEL is publicly traded, giving anyone a direct, accessible vehicle to participate in the AI frenzy.
This PR introduces:
BIEL’s role in the AI healthcare ecosystem
ActiPatch as the ready‑to‑deploy hardware platform
Zero R&D cost, zero regulatory lag, zero product‑development delay
BIEL stock as the public gateway to the AI‑bioelectronic revolution
This is the PR that wakes up the market.
PR #2 — BIEL Confirms Profitability Path as Revenues Accelerate
This is the credibility catalyst.
BIEL announces that rising ActiPatch demand, expanding distribution, and new partnerships are pushing the company toward near‑term profitability.
Key points:
Revenue growth quarter over quarter
Expanding U.S. and international distribution
Increasing reorder volume
Lower manufacturing cost per unit
Clear timeline to profitability
This PR signals to the market that BIEL is no longer a speculative story — it’s a scaling business with real revenue traction.
PR #3 — BIEL Financials Becoming Current + Quarterly Reporting Begins
This is the institutional catalyst.
BIEL announces that it is completing the process of bringing its financials current and audited, and will begin quarterly reporting going forward.
This unlocks:
Global liquidity
Access to new investors
Eligibility for uplisting pathways
Institutional visibility
Analyst coverage potential
This PR removes the final barrier preventing large money from entering the stock.
PR #4 — BIEL Announces Stock Buyback Program After Loans Are Paid Off
This is the valuation catalyst.
Once loans are paid off, BIEL announces a share buyback program — a powerful signal of confidence and a direct mechanism to increase shareholder value.
A buyback:
Reduces the float
Increases EPS
Strengthens price stability
Attracts long‑term investors
Demonstrates financial discipline
This is the PR that transforms BIEL from a turnaround story into a high‑growth, shareholder‑focused company.
THE COMPOUNDING EFFECT
Each PR builds on the previous one:
Visibility (AI pivot + zero‑cost ActiPatch + stock as AI vehicle)
Credibility (profitability approaching)
Legitimacy (audited financials + quarterly reporting)
Valuation Power (stock buyback)
This sequence is how a sub‑penny stock becomes a story stock, then a momentum stock, then a fundamental growth stock, and finally a $1+ stock.
2
